Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference ( ut Medivation Medivation Inc. is a b...)

HOME >> MEDICINE >> TECHNOLOGY

Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

ut Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation; or Lori Williams of Baylor College ofMedicine, Office of Public Affairs
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:

(Date:11/25/2009)...wswire/--Reportlinker.comannouncesthatanewmarketre...nManagement-GlobalTrends ,, http://www.repor...ds.html ,, Widespreadavailabilityofgenericdrug...ewdrugshaveacceleratedthepaceofgrowthinthepainmana...cturecontinuetoshapedemandforservices,drugsanddevi...

(Date:11/25/2009)...SYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareInte...vatorandprovideroflessinvasive,miniaturizedcircula...ofadvancedheartfailure,todayannouncedthatitissched...erJaffrayHealthCareConferenceat8:00amESTonWednesda...orkPalaceHotel,December1-2. ,, Alivewebcastofth...

(Date:11/24/2009)...RNewswire/-- ,, WHAT:RomHoubens,aBelgianmanthou...nt,wasactuallyfullyconsciousandawakeduringthattime...naVoxEyeMaxwasfeaturedinthesegmenttoillustratehowp...ockcommunication. ,, WHEN:GoodMorningAmerica-- ...xtech.com ,, WHO:RomHoubenswasanengineering...

Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2 Reportlinker Adds Pain Management - Global Trends 3 Reportlinker Adds Pain Management - Global Trends 4 Reportlinker Adds Pain Management - Global Trends 5 DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2 Olympic Silver Medalist Men 26apos 3Bs Water Polo Star Ryan Bailey Strikes Gold 61901 1 Olympic Silver Medalist Men 26apos 3Bs Water Polo Star Ryan Bailey Strikes Gold 61901 2 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3 Dr Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 61893 1 Dr Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 61893 2

[0] Reportlinker Adds Pain Management - Global Trends [0] HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City [0] DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years

...pendent Study Indicates 20-50% Improvement in Post...ood Stem Cells for Cancer,Therapy, BOTHELL, Wash.,...olutions Inc. , a leading developer and marketer o...tion media products for cells,tissues, and organs...f its CryoStor family of cryopreservation media at...

...ETTA also Showed Sustained Improvements in Blood G...AGO, June 23, 2007 /PRNewswire-FirstCall/ -- Amyli...today announced,results from a study that showed B...nts in blood sugar levels and progressive weight,l...TTA treatment,was also associated with improvement...

Other Medicine Technology:BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 2 BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 3 BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 4 Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2 Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3 Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4 Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5 Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6

BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes

(Date:11/27/2009)...,, ROCHESTER,N.Y.,Nov.27/PRNewswire-USNewswi...oviderandfortunatelyeveryyear,newvaccinesarebeinga...ostimmunityforthesameperiodoftime?And,ifnot,whenar...g? ,, Inthismonth,sissueofPediatrics,theJournal...MD,DirectoroftheRochesterGeneralResearchInstitute,...

(Date:11/27/2009)... Soaring rates to bring unprecedented medical, eco..., Nov. 27 (HealthDay News) -- The number of people... double over the next 25 years, a new study predic...ut 44.1 million people with the disease, up from 2...t of treating people with diabetes will triple, th...

(Date:11/27/2009)..., Three new interactive a... Williams & Wilkins expand health sciences lea... Durham, NC (Vocus) November...ams & Wilkins (LWW), a division of Wolters Klu...ree new anatomy education apps on the App Store. C...

(Date:11/26/2009)... Luggage that,s too big or too heavy can lead to s...ealthDay News) -- There may be nothing wrong with ...ht not want to do the same thing with your suitcas...,000 people were treated in 2008 in U.S. hospital ...er medical facilities for luggage-related injuries...

(Date:11/26/2009)..., Benton Communications a...iness growth system for retailers struggling to ma... (PRWEB) November 26, 2009 -- Flu fears is the ty...es to the emergency room, according to Dr. David B...wly released business growth system – The R...

Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2 Health News:Why Some Vaccines May Require A Booster 3 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5 Health News:Pack Right for the Holidays to Avoid the ER 2 Health News:Pharmacist Injects Cure for Ailing Businesses 2

[0] Why Some Vaccines May Require A Booster [0] Diabetes Cases Expected to Double in 25 Years [0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store [2] Pack Right for the Holidays to Avoid the ER [1] Pharmacist Injects Cure for Ailing Businesses

... fewer calories, lower sodium, and comparable ...- -Study also cites lower production costs a...C Bulletin,Board: NTRZ), a world leader in stabili...ngredient Technologies, an,independent research fi...

...sion Inc. (Nasdaq:,LCAV), a leading provider of la...(R) brand, announced the opening of its 76th Lasik...his opening marks the fourth,LasikPlus(R) vision c...l 2006., Similar to other LasikPlus(R) vision cen...

...rdiac Science,Corporation (Nasdaq: CSCX ), a glob...ion, rehabilitation, and informatics products, ann...ology conference that it completed,certification f...ased practice management and electronic medical re...

...line Health,Solutions, Inc. (Nasdaq: STRM ) today...arter and fiscal year ended January 31, 2008., Re...ere $5.6 million, a,47% increase, compared with $3... Operating Profit of $309 thousand in the,fourth q...

...31 Ingenuity Systems, the,leading provider of inf...nounced today that Path Designer, the new pathway ... New Product by the scientific community in,attend...o more clearly communicate their experimental find...

...ating the uninsured through automated eligibility...stance programs, C...its,healthcare financing method was granted United...es, in real time, patient,eligibility for financia...

NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey Cardiac Science Adds NextGen to Its Roster of Certified EMR System Partners Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference The United States Patent and Trademark Office Grants TransUnion Patent for Healthcare Financing Method

Direct Image 30° Prism SSV®

Direct Image 15° Prism SSV®

...sed stereopsis, the Central Retinal ACS is best su...regions. The Central Retinal is ideal for vitrecto...rative vitreoretinopathy extending to the equator....ctomy Lenses from Volk can be safely steam-sterili...

...far surpassing any medium magnification vitreoreti...arity, detailed visualization to the equatorial re...xtending to the equator. Available on (ACS) AutoCl...from Volk can be safely steam-sterilized and can w...

Medicine Products:

Direct Image 30° Prism SSV®Direct Image 15° Prism SSV®Central Retinal (ACS)clariVit Central Mag.

( ut Medivation Medivation Inc. is a b...)Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference,Health